A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
about
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristicsExtensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionAntibody vs. HIV in a clash of evolutionary titansComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesCurrent Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionRecent strategies targeting HIV glycans in vaccine designHIV-1 antibodies from infection and vaccination: insights for guiding vaccine designInduction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cellsAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesCrystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design ImplicationsCrystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 InteractionStructural Characterization of HIV gp41 with the Membrane-proximal External RegionStructure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external regionDistinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeA gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionAutoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimerNeutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorRecent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal AntibodiesBroadly Neutralizing Antibodies for HIV EradicationThe good and evil of complement activation in HIV-1 infectionInsensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype BRecognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicityHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesSequence variation of koala retrovirus transmembrane protein p15E among koalas from different geographic regionsBroad neutralization coverage of HIV by multiple highly potent antibodiesHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesPassive immunization against HIV/AIDS by antibody gene transfer.Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.Closing the door to human immunodeficiency virus.Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tailAntibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.
P2860
Q21090521-B3A4F871-3929-4BFE-8A01-06249A8FC8F2Q21245045-1A7AB12B-B159-41B0-8CCA-8DA48E360A95Q24536059-FA31A972-48C9-400C-AA98-60DF4BDB08F5Q24561905-B11F1920-4B4E-4653-9EE5-2BCCB23B4D44Q26775082-C449D04D-ECED-4A7A-B220-A4430824CF05Q26823603-838F9367-6D08-42C8-A2B3-1CB7B0047BD8Q27022055-3B7D1F43-C1A9-433D-9A12-3DFFC963256DQ27312171-0096A7D4-DEC3-4A22-ABE4-DFD1EF446D6AQ27320687-568B7489-F44E-4933-9296-8788C212C494Q27489000-2B98190F-A0F3-4837-A748-57F7E06DDE48Q27657377-5F792AFC-8603-4727-8BE6-DC49342A53ADQ27661588-869009D2-3ADC-4ADF-987A-AF9C17BF8253Q27662117-78C28B3F-3E74-4066-AEDB-77CCCE5CBA79Q27662155-272D6219-DE82-44B8-A2B8-CDB0529FF6C3Q27665883-423BF47A-E00F-4635-9035-E274D3F6FBAFQ27665884-4D5E3DD1-A3A5-4FCB-8670-C0D1950FFFF6Q27675260-B25CF2DE-AB0F-426F-87C6-EAD5573D841AQ27676864-E0A2CB17-575A-4455-ADE3-4A5AEB707786Q27680125-67A7BBDB-D0F4-4662-B761-0F7A88CAD8A4Q27681501-484B0119-B4FB-41E9-9439-084E3C0BA328Q27684529-180858F2-8EDA-42DF-97BC-76B368B04D4AQ28068946-1F3CCD1C-3E3A-4DFB-90DC-1F53C14D102DQ28073939-6A64D507-74E5-4527-9F80-6EC551557AEDQ28275986-B286854F-FEAF-4A27-8A37-BE2F2B4B8E24Q28469023-6501AED1-25A6-435A-8547-F27BAE884A1FQ28484544-89A61E36-D792-4B4E-98A5-368045DC4302Q28602877-B0AB8B4A-F4E6-421E-9628-299D66074081Q28651078-66A5B0CE-43E7-4231-A729-B3357D3871C1Q29615361-7713FF73-BC93-458C-9426-426361B6E367Q29619015-670AFDE4-1C61-40FE-B23C-6D8F5E3506B5Q30358434-1B25C6CB-22DF-4962-B9B8-97E1093BBD4BQ30358769-D323A349-4524-4086-8B79-6886FFB2B7D8Q30425594-FB191217-8846-4F24-9C85-3CFC5B3A0185Q30428089-3A0DD23C-26DE-42F6-86F1-2634A327FA0AQ30524110-B0E41DF3-83C3-4F12-AABC-54E6FBB4C290Q30843874-31E3ABFB-D6DB-4388-8D32-64E3B07555BDQ31132248-342A9AA1-E435-467D-AC4B-B2D2F4CB2FC3Q31143293-702F9A90-3689-4B3C-BECF-647483D133A0Q33205911-A4C9F90C-2D59-43B5-8F85-9B895CE81DDFQ33262382-1761FD34-118B-420F-84F4-0932B6CD6321
P2860
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
A potent cross-clade neutraliz ...... immunodeficiency virus type 1.
@en
type
label
A potent cross-clade neutraliz ...... immunodeficiency virus type 1.
@en
prefLabel
A potent cross-clade neutraliz ...... immunodeficiency virus type 1.
@en
P2093
P1476
A potent cross-clade neutraliz ...... immunodeficiency virus type 1
@en
P2093
Katinger H
Purtscher M
Stiegler G
Voglauer R
P304
P356
10.1089/08892220152741450
P577
2001-12-01T00:00:00Z